The blockers of exosomes SIRP α and CD47 can enhance the phagocytic function of cancer cells, suggesting that targeting SIRP α with antibodies presents a promising immunotherapy approach for treating tumors exhibiting high expression of SIRP α, such as renal cell carcinoma and melanoma (Yanagita et al., 2017). This evidence concerns the gene SIRPA and cancer.